Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Ibrutinib as a single agent and in combination with dexamethasone showed anti-tumour activity in multiple myeloma

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.14
Views: 2299

Dr Ravi Vij - Washington University School of Medicine, St Louis, USA

Dr Vij talks to ecancertv at ASH 2014 about his work looking at the use of ibrutinib, as a single agent and in combination with dexamethasone in heavily pre-treated multiple myeloma patients.

There was evidence of anti-tumour activity.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation